News

Vaccination of primates against toxoplasmosis at Pairi Daiza.

Monday, February 01st 2021

Vaxinano is proud to participate to the protection of endangered species against lethal toxoplasmosis

New contract signed

Thursday, January 14th 2021

This important contract signed with a major veterinary vaccine company will allow to develop the studies ongoing and is an important step for both companies declares Pr Didier Betbeder

New contract signed

Wednesday, December 23rd 2020

Vaxinano announces the signature of a new contract with a vaccine veterinary company. This contract demonstrates the interest of this company to pursue studies with our technology declares Pr Didier Betbeder.

GMP batches of Vaxinano particles for clinical trials were performed by Stanipharm.

Tuesday, October 20th 2020

« This is a great news for the company that allows to go further for the development of our vaccines for clinical trials announces Pr Didier Bebeder »

Vaxinano: A vaccine against toxoplasmosis for Saïmiris monkeys

Friday, October 16th 2020

In this article, Vaxinano and the laboratory BioMAP (INRAE) have vaccinated non-human primates against toxoplasmosis with the support of french zoos.

The first non-living vaccine against toxoplasmosis: a world premiere by Vaxinano. (Ducournau C. & al. Front. Immunol. 2020)

Wednesday, September 09th 2020

In this publication, Vaxinano’s nasal vaccine administered using a nasal spray protects sheep against chronic and congenital Toxoplasma gondii infection (Ducournau C. & al. Front. Immunol. 2020). This vaccine will also benefit the general public health by reducing the socio-economic burden associated to the consumption of contaminated meat, the major source of human toxoplasmosis.

Crossing the mucus barrier with a nasal vaccine: a strong breakthrough by Vaxinano. (Fasquelle F. & al. ACS Appl. Bio Mater. 2020 )

Monday, August 03rd 2020

Mucus is a natural barrier that impedes pathogens to invade the body and initiate infection. Contrary to most nanocarriers, Vaxinano’s starch nanoparticles are able to cross the mucus layer and induce an immune protective response (Fasquelle F. & al., ACS Appl. Bio Mater. 2020). This explains why Vaxinano’s vaccines are efficient via the mucosal administration route, acting against a large number of pathogens - such as Influenza viruses and Toxoplasma gondii - without the addition of any adjuvants (Le MQ. & al., Int. J. Pharm. 2020; Ducournau C. & al., Front. Immunol. 2020).

Vaxinano’s technology in use against the coronavirus pandemic.

Tuesday, June 30th 2020

The French research national agency (ANR) has granted Vaxinano funding to develop an innovative vaccine against Covid-19.

Vaxinano recruits an animal vaccine project leader

Wednesday, April 29th 2020

The Vaxinano's technology, high hope for Covid-19 vaccine (Le MQ. & al., Int. J. Pharm. 2020)

Thursday, April 16th 2020

Nasal vaccination with Vaxinano's nanoparticles against flu virus inhibits virus transmission

Didier Betbeder, CEO & CSO of Vaxinano, interviewed in Parole d'Experts de La Tribune (french)

Wednesday, February 12th 2020

Didier Betbeder, CEO & CSO of Vaxinano, explains how innovative and efficient is its vaccine platform.